Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cadrenal Therapeutics Inc (CVKD)

Cadrenal Therapeutics Inc (CVKD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,102
  • Shares Outstanding, K 2,338
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,650 K
  • EBIT $ -15 M
  • EBITDA $ -15 M
  • 60-Month Beta 1.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.21
  • Number of Estimates 1
  • High Estimate -1.21
  • Low Estimate -1.21
  • Prior Year -2.74
  • Growth Rate Est. (year over year) +55.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.42 +32.87%
on 12/30/25
12.50 -31.76%
on 12/15/25
-2.47 (-22.45%)
since 12/12/25
3-Month
6.42 +32.87%
on 12/30/25
14.50 -41.17%
on 10/13/25
-5.09 (-37.37%)
since 10/10/25
52-Week
6.42 +32.87%
on 12/30/25
22.90 -62.75%
on 02/26/25
-7.74 (-47.57%)
since 01/10/25

Most Recent Stories

More News
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX...

SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current...

CVKD : 8.53 (+4.41%)
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026

PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current...

CVKD : 8.53 (+4.41%)
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HIT It is the first and only  potent, highly selective inhibitor of human 12-LOX in clinical...

CVKD : 8.53 (+4.41%)
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation...

PTCT : 77.59 (+0.08%)
CVKD : 8.53 (+4.41%)
Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award

PONTE VEDRA, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation...

CVKD : 8.53 (+4.41%)
Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation...

CVKD : 8.53 (+4.41%)
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation...

CVKD : 8.53 (+4.41%)
Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors

Acquisition significantly enhances the Company’s pipeline by adding novel assets in acute and chronic anticoagulation settings Company is strategically poised to deliver differentiated therapeutics...

CVKD : 8.53 (+4.41%)
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Announces strategic clinical trial plans for tecarfarin in patients with End-Stage Kidney Disease (ESKD) transitioning to dialysis Tecarfarin...

CVKD : 8.53 (+4.41%)
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

Advances knowledge about the use of tecarfarin in patients with severe kidney impairment, including dialysis Pivotal...

CVKD : 8.53 (+4.41%)

Business Summary

Cadrenal Therapeutics Inc. is a biopharmaceutical company. It focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. Cadrenal...

See More

Key Turning Points

3rd Resistance Point 9.24
2nd Resistance Point 8.95
1st Resistance Point 8.74
Last Price 8.53
1st Support Level 8.24
2nd Support Level 7.95
3rd Support Level 7.74

See More

52-Week High 22.90
Fibonacci 61.8% 16.61
Fibonacci 50% 14.66
Fibonacci 38.2% 12.72
Last Price 8.53
52-Week Low 6.42

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar